Singapore: WuXi PharmaTech entered into a contract manufacturing agreement with TaiMed Biologics for the manufacture of ibalizumab (TMB-355) in support of phase II and phase III clinical trials globally.

Ibalizumab is a humanized monoclonal antibody and a member of an emerging class of HIV therapies known as viral-entry inhibitors. This work will be completed at WuXi's biologics manufacturing facilities in China and its biologics testing facilities in the US.

"We are pleased that TaiMed Biologics has selected WuXi to manufacture ibalizumab for its global clinical trials because of WuXi's strong technical capabilities and high quality standards," said Mr Edward Hu, COO, WuXi PharmaTech. "WuXi's integrated biological drug discovery, development, manufacturing and testing service platform provides our customers with a seamless solution to bring their biologics products to the market globally and in China."

Mr James Chang, CEO, TaiMed Biologics, said that, "TaiMed looks forward to working with WuXi to produce clinical-trial supplies of this important new medicine for patients," said  "We are delighted to have such a skilled and reputable partner in WuXi for late-stage manufacturing as we further develop the subcutaneous formulation of our lead product, ibalizumab."